KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Thermo Fisher Scientific (TMO) Goodwill (2016 - 2025)

Thermo Fisher Scientific (TMO) has disclosed Goodwill for 16 consecutive years, with $43.8 billion as the latest value for Q2 2024.

  • For the quarter ending Q2 2024, Goodwill rose 1.32% year-over-year to $43.8 billion, compared with a TTM value of $43.8 billion through Jun 2024, up 1.32%, and an annual FY2023 reading of $44.0 billion, up 6.86% over the prior year.
  • Goodwill was $43.8 billion for Q2 2024 at Thermo Fisher Scientific, roughly flat from $43.8 billion in the prior quarter.
  • Across five years, Goodwill topped out at $44.0 billion in Q4 2023 and bottomed at $25.6 billion in Q1 2020.
  • Average Goodwill over 5 years is $36.2 billion, with a median of $41.1 billion recorded in 2022.
  • The sharpest move saw Goodwill skyrocketed 60.99% in 2021, then dropped 1.74% in 2022.
  • Year by year, Goodwill stood at $26.0 billion in 2020, then skyrocketed by 60.99% to $41.9 billion in 2021, then decreased by 1.74% to $41.2 billion in 2022, then increased by 6.86% to $44.0 billion in 2023, then fell by 0.4% to $43.8 billion in 2024.
  • Business Quant data shows Goodwill for TMO at $43.8 billion in Q2 2024, $43.8 billion in Q1 2024, and $44.0 billion in Q4 2023.